Prostate Cancer: Understanding Your Options Beyond What Your Urologist Says

Of all the cancer diagnoses that a man can receive, prostate cancer is among the most variable in what it actually means for his health and his life. Some prostate cancers are aggressive — fast-growing, prone to spreading, requiring prompt and decisive treatment. Others are so slow-growing that a man diagnosed with them at 65 is statistically more likely to die of something else entirely than to die of the cancer, and aggressive treatment would cause more harm than the disease itself.

The challenge is that both kinds of prostate cancer look like "cancer" — and in the medical system, cancer is a word that tends to produce urgency. A patient who hears that word often begins moving toward treatment before he has fully understood what kind of cancer he has, whether it poses a meaningful risk to his health, and whether the treatment being recommended is actually the best option for his specific situation.

This matters because prostate cancer treatment is not without consequences. Surgery carries risks of incontinence and erectile dysfunction that can significantly affect quality of life. Radiation carries its own side effect profile. Hormone therapy affects energy, mood, bone density, and sexual function. These are meaningful trade-offs — ones that are worth accepting when treatment is genuinely necessary, and not worth accepting when it isn't.

The range of appropriate options for prostate cancer is wider than most patients are told in a single appointment with a single specialist. Understanding that range — and understanding how to evaluate where a specific diagnosis falls within it — is what this article is about.

The Spectrum of Prostate Cancer

Prostate cancer is graded using the Gleason score and the more recently adopted Grade Group system, both of which reflect how abnormal the cancer cells look under a microscope and how aggressively the cancer is likely to behave. Grade Group 1 (Gleason 6) represents the most indolent end of the spectrum — low-risk cancer that grows slowly and rarely spreads. Grade Groups 4 and 5 (Gleason 8-10) represent high-risk cancers that require prompt, aggressive treatment. Grade Groups 2 and 3 occupy the intermediate range, where the appropriate treatment depends on additional factors.

PSA level — the blood test that measures prostate-specific antigen — is another key component of risk stratification. A single PSA value is less informative than the trend over time: how quickly the PSA is rising, and in the context of prior values, what that trajectory suggests about the cancer's behavior.

Staging — based on imaging studies that evaluate whether the cancer is confined to the prostate or has spread to nearby lymph nodes or distant sites — completes the picture. The combination of grade, PSA, and stage places a patient within a risk category that drives the treatment conversation.

Understanding where a specific prostate cancer sits on this spectrum is the prerequisite for an informed treatment discussion. A patient who has been told he has prostate cancer without being given a clear explanation of his grade group, his PSA trend, and his staging has not yet been given the information he needs to evaluate his options.

Active Surveillance: What It Is and When It Applies

Active surveillance is not watchful neglect. It is a structured monitoring approach — involving regular PSA testing, periodic prostate biopsies, and sometimes MRI imaging — that tracks the cancer's behavior over time and moves to treatment if the cancer shows signs of progression.

For men with low-risk prostate cancer (Grade Group 1, low PSA, disease confined to the prostate), active surveillance is now widely recognized as the appropriate standard of care by major oncology guidelines. This represents a significant evolution from the approach of a generation ago, when virtually all diagnosed prostate cancers were treated aggressively. The change reflects accumulating evidence that treatment for low-risk disease produces harm — in the form of incontinence, erectile dysfunction, and other side effects — without meaningful improvement in survival.

For some men with favorable intermediate-risk disease (Grade Group 2), active surveillance is also a legitimate option, depending on additional clinical factors. The conversation about whether active surveillance is appropriate for intermediate-risk disease is one that benefits from subspecialty input from a physician experienced in this specific decision.

What active surveillance is not is the same as no surveillance. Men on active surveillance need to be adherent to the monitoring protocol — regular PSA testing, biopsies at appropriate intervals, and immediate response if the cancer shows signs of progression. Active surveillance works because it catches progression early, when treatment can still be curative. A patient who agrees to active surveillance but doesn't follow through with monitoring is not getting the benefit of the approach.

The Treatment Options: What They Are, What They Do

For men whose cancer warrants treatment — because of grade, stage, PSA trajectory, or progression on surveillance — the menu of options is wider than a single specialist's recommendation often reflects.

Radical prostatectomy — surgical removal of the prostate — is the recommendation that many men receive first, often from a urologist. It is an effective treatment for localized prostate cancer, with well-established long-term outcomes data. It also carries well-established risks: incontinence (ranging from mild leakage to significant incontinence) affects a meaningful proportion of men after surgery, and erectile dysfunction is common, with recovery varying substantially by age and pre-operative function. Robotic-assisted surgery has improved precision and in many cases reduced side effects compared to open surgery, but the risk profile is not eliminated.

Radiation therapy — either external beam radiation delivered over several weeks, or brachytherapy (radioactive seeds implanted in the prostate) — is an alternative to surgery for localized prostate cancer with comparable survival outcomes for appropriate candidates. The side effect profile differs from surgery: radiation is more likely to affect bowel function and bladder function in specific ways, and erectile dysfunction is common though the onset may be more gradual than with surgery. Stereotactic body radiotherapy, a form of high-precision external beam radiation delivered in a smaller number of larger doses, has become more widely used in recent years.

Hormone therapy — androgen deprivation therapy, which reduces testosterone levels to slow cancer growth — is used in combination with radiation for intermediate and high-risk localized disease, and as the primary treatment for advanced or metastatic prostate cancer. Its side effects are significant: fatigue, hot flashes, loss of libido, loss of bone density, metabolic changes, and mood effects are common. For advanced disease, hormone therapy extends life and reduces symptoms; for localized disease, its role is as an adjunct to radiation rather than as a standalone treatment.

Focal therapy — techniques including high-intensity focused ultrasound (HIFU) and cryotherapy — treats only the part of the prostate where the cancer is located, rather than the entire gland. Focal therapy is not appropriate for all patients — its use is most relevant for carefully selected men with localized, unifocal disease — but for appropriate candidates it represents an option that may reduce side effects compared to whole-gland treatments. The evidence base for focal therapy is still developing relative to surgery and radiation, and it is not available at all centers.

Chemotherapy and novel hormonal agents — medications including enzalutamide, abiraterone, and docetaxel — are used in the management of castration-resistant prostate cancer (cancer that has progressed despite standard hormone therapy) and in high-risk settings in combination with hormone therapy.

PARP inhibitors and immunotherapy represent newer treatment approaches for specific molecular subtypes of prostate cancer — particularly those with mutations in DNA repair genes such as BRCA1 and BRCA2. Genetic testing for these mutations is increasingly important in prostate cancer management, both for treatment selection and for implications for family members.

Why Treatment Recommendations Vary So Much

The variation in treatment recommendations for prostate cancer is among the most extensively documented in oncology. Studies have consistently found that the recommendation a patient receives depends significantly on which specialist he sees first — not just on the characteristics of his cancer.

A urologist, whose specialty is surgical, is more likely to recommend surgery. A radiation oncologist is more likely to recommend radiation. This is not dishonesty — both specialists may genuinely believe their recommended approach is best for the patient. It is a reflection of the fact that expertise shapes perspective, and that for intermediate-risk prostate cancer in particular, the evidence comparing surgery and radiation does not definitively favor one approach over the other. The "right" treatment depends on factors including the patient's age, health status, values, side effect preferences, and the specific characteristics of the cancer — and different specialists weigh those factors differently.

This is exactly why seeing only the first specialist who makes a recommendation is a high-risk approach to prostate cancer treatment decisions. The recommendation of a urologist is the beginning of the conversation, not the end of it. Understanding what a radiation oncologist would recommend, what a multidisciplinary tumor board at a major cancer center would conclude, and what the most current evidence says about the options for a patient with this specific cancer profile is what informed decision-making requires.

The Case of Overlooked Bloodwork

One of the cases that came to Pilot Rock Medical Navigators involved a patient with a history of prostate cancer whose follow-up bloodwork contained PSA values that were rising in a pattern consistent with recurrence. The values were there, in the record, available to anyone who looked at them carefully in the context of the patient's history.

They had not received the clinical attention they warranted.

When Pilot Rock reviewed the patient's records, the rising PSA trend was identified and the appropriate response was set in motion. The recurrence was caught at a point when intervention was still meaningful — rather than at a later point when the disease had progressed further.

This case illustrates something important about prostate cancer surveillance specifically. PSA monitoring after treatment is the primary tool for detecting recurrence, and rising PSA values — even when they remain within ranges that might not trigger immediate alarm — can be the earliest signal of a problem. Reading those values in context, tracking them over time, and recognizing when the trend is concerning requires someone who has the full history and the time to look at it carefully. For patients whose post-treatment surveillance is managed in the fragmented way that standard primary care often provides, that comprehensive oversight may not exist unless someone actively creates it.

Pilot Rock and the Multidisciplinary Prostate Cancer Conversation

For patients facing a prostate cancer diagnosis who want to ensure they have the full picture before making a treatment decision, Pilot Rock Medical Navigators has facilitated referrals to major academic centers with specialized prostate cancer programs — including Mount Sinai — where multidisciplinary evaluation by surgeons, radiation oncologists, and medical oncologists can provide the kind of comprehensive recommendation that a single specialist consultation cannot.

This kind of multidisciplinary evaluation is the standard of care at major academic cancer centers and the approach most likely to produce a treatment recommendation that reflects the full range of evidence and the patient's individual situation. For patients whose initial recommendation came from a single specialist, seeking this kind of comprehensive evaluation before committing to a treatment course is a meaningful step.

The goal is not to contradict the initial recommendation. In many cases, the multidisciplinary evaluation confirms it. The goal is to ensure that when a treatment decision is made — one that will affect quality of life for years — it is made with the benefit of the most relevant expertise, the most complete information, and the most current evidence.

Questions Every Patient Should Ask

Before agreeing to any prostate cancer treatment, there are questions worth asking of every specialist involved.

What is my specific grade group, PSA level, and stage, and what risk category does that place me in? Am I a candidate for active surveillance, and if not, why not? What are all of the treatment options for my risk category, and what does the evidence say about how they compare? What are the realistic side effect profiles for each option — not the best case, but the expected case for someone with my age and health? What would a radiation oncologist recommend for my case? What would a multidisciplinary tumor board at a major cancer center conclude? Are there clinical trials relevant to my diagnosis? And if I choose treatment, what does follow-up surveillance look like afterward?

A specialist who engages seriously with all of these questions is providing the kind of consultation that complex, consequential decisions deserve. One who dismisses some of them is telling the patient something important about the completeness of their perspective.

Prostate cancer is often a manageable, survivable condition — particularly when diagnosed early and managed appropriately. The key word is appropriately, which means with the right level of treatment for the specific cancer's risk, the right expertise guiding the decision, and the right oversight in place afterward to catch any problems that develop. Getting to "appropriately" is what the second opinion, the multidisciplinary evaluation, and the independent record review are designed to ensure.

______________

If you or a loved one has received a prostate cancer diagnosis and wants to understand all the options before making a treatment decision, Pilot Rock Medical Navigators can help. Book a free 15-minute introductory call to discuss your situation. Learn how Pilot Rock can help →